Perrigo’s HRA Pharma has submitted an application to the US Food and Drug Administration (FDA) for possible future approval of the first-ever OTC birth control pill.
HRA Pharma, a Perrigo company, has announced it submitted an application to the US Food and Drug Administration (FDA) for possible future approval of the first-ever OTC birth control pill.1
This application is for an Rx-to-OTC switch for Opill (HRA Pharma), which is a progestin-only (or non-estrogen) daily birth control pill. Currently, Opill is approved by the FDA in 19731 to prevent pregnancy and has been an available progestin-only option for more than 50 years.
In a company press release announcing the submission, HRA Pharma said that removing the prescription hurdle to the pill would in turn improve access to a contraceptive “that is well tolerated and notably more effective at preventing pregnancy than all current methods available OTC.”
Further, the American College of Obstetricians and Gynecologists, the American Medical Association, and the American Academy of Family Physicians, have all voiced support for making birth control pills available OTC.
"As a doctor, I am dedicated to empowering people to make decisions about pregnancy prevention. For many, a birth control pill may be the best option for them but requiring a prescription is an unnecessary obstacle that can put it out of reach," said obstetrician-gynecologist, Melissa J. Kottke, MD, MPH, MBA. "Removing the prescription requirement for a progestin-only birth control pill will be a historic advancement for pregnancy prevention and a remarkable achievement in community public health."
An approval decision is expected sometime next year, according to the company.
Reference
1. Perrigo’s hra pharma submits application to fda for first-ever otc birth control pill. HRA_Pharma. Published July 11, 2022. Accessed July 11, 2022. https://www.hra-pharma.com/articles/perrigos-hra-pharma-submits-application-to-fda-for-first-ever-otc-birth-control-pill-66
Recap on reproductive rights with David Hackney, MD, MS
December 20th 2022In this episode of Pap Talk, we spoke with David Hackney, MD, MS, maternal-fetal medicine physician at Case Western Reserve University and chair of ACOG's Ohio chapter for a full recap of where restrictions on reproductive rights have been and where they're going.
Listen
In this episode of Pap Talk, Gloria Bachmann, MD, MSc, breaks down what it means to be a health care provider for incarcerated individuals, and explores the specific challenges women and their providers face during and after incarceration. Joined by sexual health expert Michael Krychman, MD, Bachmann also discusses trauma-informed care and how providers can get informed.
Listen
Preference for alternative contraceptive sources reported by many patients
October 31st 2024With nearly half of short-acting contraceptive users preferring non-traditional sources such as telehealth and over-the-counter options, a recent study highlights evolving patient needs in contraceptive access.
Read More